{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T11:12:50Z","timestamp":1789816370830,"version":"4.0.1"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005047","name":"Natural Science Foundation of Liaoning Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005047","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Developing effective drugs for Alzheimer\u2019s Disease (AD) is critically limited by insufficient brain exposure. To address this, structural optimization was employed to balance physicochemical properties and enhance blood-brain barrier (BBB) permeability, resulting in the development of ZJCK-6-72, a novel DYRK1A inhibitor. This study aims to comprehensively evaluate the drug-like properties and safety profile of ZJCK-6-72.<\/jats:p>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A comprehensive\n                      <jats:italic>in vitro<\/jats:italic>\n                      and\n                      <jats:italic>in vivo<\/jats:italic>\n                      ADMET (absorption, distribution, metabolism, excretion, and toxicity) profiling of ZJCK-6-72 was conducted. Key assessments included pharmacokinetics, tissue distribution studies in rats, plasma protein binding assays, and metabolic stability testing. Additionally, acute toxicity was evaluated to determine the safety margin, and enzyme inhibition assays were performed to assess potential drug-drug interactions.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      ZJCK-6-72 exhibited excellent oral bioavailability (78.03%) and extensive tissue distribution in rats. Notably, the compound demonstrated substantially enhanced brain penetration, with a brain-to-plasma ratio ranging from 1.92 to 4.63. The unbound brain-to-plasma partition coefficient (K\n                      <jats:sub>p, uu<\/jats:sub>\n                      ) was determined to be 3.50, significantly exceeding unity. Metabolic studies indicated a shift towards CYP1A2 and CYP2C19 mediated pathways, with concentration-dependent inhibition observed (IC\n                      <jats:sub>50<\/jats:sub>\n                      \u2248 1.8\u00a0\u03bcM). The acute toxicity assessment revealed an LD\n                      <jats:sub>50<\/jats:sub>\n                      of 233.9\u00a0mg\/kg bodyweight.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>\n                      The high K\n                      <jats:sub>p, uu<\/jats:sub>\n                      value indicates that the efficient brain entry of ZJCK-6-72 is likely driven by active uptake mechanisms rather than simple passive diffusion, confirming its ability to effectively evade efflux transporters. Although the inhibition of CYP1A2 and CYP2C19 suggests a potential for mechanism-based auto-inhibition, the acute toxicity profile demonstrates an acceptable safety margin for therapeutic development.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>ZJCK-6-72 displays an optimized pharmacokinetics profile characterized by superior unbound brain exposure. These findings support the potential of ZJCK-6-72 as a promising lead candidate for CNS-targeted AD therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1792258","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T05:35:18Z","timestamp":1777613718000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Pharmacokinetics, distribution, metabolism, excretion and safety characterization of ZJCK-6-72: novel DYRK1A inhibitor with optimized brain exposure for Alzheimer\u2019s disease therapy"],"prefix":"10.3389","volume":"17","author":[{"given":"Zhenshu","family":"Li","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, General Hospital of Northern Theater Command","place":["Shenyang, China"]},{"name":"Graduate School of China Medical University, China Medical University","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanhua","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, General Hospital of Northern Theater Command","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinzhu","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, General Hospital of Northern Theater Command","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aizhu","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, General Hospital of Northern Theater Command","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinpeng","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, General Hospital of Northern Theater Command","place":["Shenyang, China"]},{"name":"Graduate School of China Medical University, China Medical University","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyuan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, General Hospital of Northern Theater Command","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyue","family":"Ning","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, General Hospital of Northern Theater Command","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijun","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, General Hospital of Northern Theater Command","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangyuan","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, General Hospital of Northern Theater Command","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanghua","family":"Xun","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, General Hospital of Northern Theater Command","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bei","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, General Hospital of Northern Theater Command","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaling","family":"Cui","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, General Hospital of Northern Theater Command","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, General Hospital of Northern Theater Command","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xudong","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, General Hospital of Northern Theater Command","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zihua","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, General Hospital of Northern Theater Command","place":["Shenyang, China"]},{"name":"Graduate School of China Medical University, China Medical University","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingchun","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, General Hospital of Northern Theater Command","place":["Shenyang, China"]},{"name":"Graduate School of China Medical University, China Medical University","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"118329","DOI":"10.1016\/j.biopha.2025.118329","article-title":"Population pharmacokinetic-pharmacodynamic modeling of co-administered N,N-Dimethyltryptamine and harmine in healthy subjects","volume":"189","author":"\u00c4bel\u00f6","year":"2025","journal-title":"Biomed. Pharmacother."},{"key":"B2","doi-asserted-by":"publisher","first-page":"3708","DOI":"10.1002\/alz.13809","article-title":"Alzheimer's disease facts and figures","volume":"20","year":"2024","journal-title":"Alzheimers Dement."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1524627","DOI":"10.3389\/fnut.2025.1524627","article-title":"The double-edged sword of nutraceuticals: comprehensive review of protective agents and their hidden risks","volume":"12","author":"Ashrafpour","year":"2025","journal-title":"Front. Nutr."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1111\/acel.12648","article-title":"Dyrk1 inhibition improves Alzheimer's disease-like pathology","volume":"16","author":"Branca","year":"2017","journal-title":"Aging Cell."},{"key":"B5","doi-asserted-by":"publisher","first-page":"12571","DOI":"10.1021\/acs.jmedchem.4c00483","article-title":"Discovery of ZJCK-6-46: a potent, selective, and orally available dual-specificity tyrosine phosphorylation-regulated kinase 1A inhibitor for the treatment of alzheimer's disease","volume":"67","author":"Chen","year":"2024","journal-title":"J. Med. Chem."},{"key":"B6","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/aps.2010.218","article-title":"Substrate-dependent modulation of the catalytic activity of CYP3A by erlotinib","volume":"32","author":"Dong","year":"2011","journal-title":"Acta Pharmacol. Sin."},{"key":"B7","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1002\/psp4.12350","article-title":"Assessing CYP2C19 ontogeny in neonates and infants using physiologically based pharmacokinetic models: impact of enzyme maturation versus inhibition","volume":"8","author":"Duan","year":"2019","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"6344","DOI":"10.1523\/jneurosci.2551-21.2022","article-title":"DYRK1A regulates the bidirectional axonal transport of APP in human-derived neurons","volume":"42","author":"Fernandez Bessone","year":"2022","journal-title":"J. Neurosci."},{"key":"B9","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s40264-016-0443-8","article-title":"Drug interactions of direct-acting oral anticoagulants","volume":"39","author":"Fitzgerald","year":"2016","journal-title":"Drug Saf."},{"key":"B10","volume-title":"Globally harmonized system of classification and labelling of chemicals (GHS). Eleventh revised edition","year":"2024"},{"key":"B11","doi-asserted-by":"publisher","first-page":"6324","DOI":"10.1111\/j.1742-4658.2009.07346.x","article-title":"Harmine specifically inhibits protein kinase DYRK1A and interferes with neurite formation","volume":"276","author":"G\u00f6ckler","year":"2009","journal-title":"Febs J."},{"key":"B12","doi-asserted-by":"publisher","first-page":"9569","DOI":"10.1021\/jm401049v","article-title":"Development of DANDYs, new 3,5-diaryl-7-azaindoles demonstrating potent DYRK1A kinase inhibitory activity","volume":"56","author":"Gourdain","year":"2013","journal-title":"J. Med. Chem."},{"key":"B13","doi-asserted-by":"publisher","first-page":"100657","DOI":"10.1016\/j.lanepe.2023.100657","article-title":"The affordability of lecanemab, an amyloid-targeting therapy for alzheimer's disease: an EADC-EC viewpoint","volume":"29","author":"J\u00f6nsson","year":"2023","journal-title":"Lancet Reg. Health Eur."},{"key":"B14","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1124\/dmd.111.043505","article-title":"Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity","volume":"40","author":"Lee","year":"2012","journal-title":"Drug Metab. Dispos."},{"key":"B15","doi-asserted-by":"publisher","first-page":"114062","DOI":"10.1016\/j.ejmech.2021.114062","article-title":"DYRK1A inhibitors for disease therapy: current status and perspectives","volume":"229","author":"Liu","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1111\/bcp.13329","article-title":"Assessment of effect of CYP3A inhibition, CYP induction, OATP1B inhibition, and high-fat meal on pharmacokinetics of the JAK1 inhibitor upadacitinib","volume":"83","author":"Mohamed","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"111813","DOI":"10.1016\/j.ejmech.2019.111813","article-title":"Structural attributes influencing unbound tissue distribution","volume":"185","author":"Orozco","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"B18","doi-asserted-by":"publisher","first-page":"13954","DOI":"10.3390\/ijms232213954","article-title":"Alzheimer's disease: treatment strategies and their limitations","volume":"23","author":"Passeri","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B19","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.1021\/jm501535r","article-title":"CNS drug design: balancing physicochemical properties for optimal brain exposure","volume":"58","author":"Rankovic","year":"2015","journal-title":"J. Med. Chem."},{"key":"B20","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.jconrel.2024.01.047","article-title":"Alzheimer's disease current therapies, novel drug delivery systems and future directions for better disease management","volume":"367","author":"Singh","year":"2024","journal-title":"J. Control Release"},{"key":"B21","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s40478-019-0678-6","article-title":"Inhibition of DYRK1A proteolysis modifies its kinase specificity and rescues alzheimer phenotype in APP\/PS1 mice","volume":"7","author":"Souchet","year":"2019","journal-title":"Acta Neuropathol. Commun."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1111\/bcp.16154","article-title":"Clinical pharmacology considerations and drug-drug interactions with long-acting cabotegravir and rilpivirine relevant to Sub-Saharan Africa","volume":"90","author":"Steulet","year":"2024","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B23","volume-title":"Oecd guidelines for the testing of chemicals acute Oral Toxicity \u2013 up-and-down-procedure (UDP)","year":"2008"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1124\/dmd.111.039065","article-title":"Evaluation of CYP2C8 inhibition in vitro: utility of montelukast as a selective CYP2C8 probe substrate","volume":"39","author":"VandenBrink","year":"2011","journal-title":"Drug Metab. Dispos."},{"key":"B25","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s00280-020-04131-y","article-title":"Physiologically based pharmacokinetic modeling to assess metabolic drug-drug interaction risks and inform the drug label for fedratinib","volume":"86","author":"Wu","year":"2020","journal-title":"Cancer Chemother. Pharmacol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1007\/s13311-023-01405-0","article-title":"Anti-amyloid immunotherapies for alzheimer's disease: a 2023 clinical update","volume":"20","author":"Yadollahikhales","year":"2023","journal-title":"Neurotherapeutics"},{"key":"B27","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41392-024-01911-3","article-title":"Recent advances in alzheimer's disease: mechanisms, clinical trials and new drug development strategies","volume":"9","author":"Zhang","year":"2024","journal-title":"Signal Transduct. Target Ther."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1792258\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T05:35:19Z","timestamp":1777613719000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1792258\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":27,"alternative-id":["10.3389\/fphar.2026.1792258"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1792258","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,1]]},"article-number":"1792258"}}